Regeneron's Revenues Nearly Triple; Eylea Launch Still Strong
By Catherine Shaffer
Wednesday, August 8, 2012
A strong launch of Eylea (aflibercept injection) for age-related macular degeneration led Regeneron Pharmaceuticals Inc.'s revenues for the second quarter, with $194 million in sales.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.